700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ ReadersThis Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
A number of nanotechnology-enabled drug delivery platforms are in varying stages of drug development. While, physiologically-based pharmacokinetic (PBPK) modelling has become a well-established tool for conventional medicines from preclinical to post-licensing environments, its application for nanomedicines is in its infancy. Part of the reason for this is that the fundamental mechanisms that underpin drug-handling within the body are not as well understood for nanoparticles. A number of recent initiatives aim to further develop PBPK modelling for nanomedicine applications but more fundamental knowledge of the relevant anatomical, physiological and pharmacological processes influencing distribution is required for robust computational prediction.
pharmacokinetic, nanomedicines, nanoformulations, Pharmacy Practice, Pharmaceutics